AUREOMYCIN®
(chlortetracycline)

EARLY, IN-FEED DEFENSE FOR HIGH-RISK CALVES

FDA-approved Aureomycin provides trusted control and treatment of bovine respiratory disease (BRD) and bacterial enteritis, and control of anaplasmosis in beef cattle during high-risk periods.

Disease prevention and risk management are about protecting well-being. Aureomycin provides early, in-feed control of BRD and anaplasmosis during high-risk periods.

THE AUREOMYCIN ADVANTAGE

- ✓ Designed for cattle facing stress from weaning, transportation and co-mingling; stress that increases the risk of BRD and other infections.
- ✓ Easy to administer in-feed, reducing the need for individual handling and trips to the chute, while minimizing stress on newly arrived cattle.
- ✓ Aureomycin can be easily incorporated into existing programs, ensuring consistent intake and effectiveness.

HOW IT WORKS

Chlortetracycline is bacteriostatic and interferes with binding of the aminoacyl-tRNA to the acceptor site on the mRNA-ribosome complex, disabling protein synthesis and preventing normal function and growth. This can occur at concentrations as low as 0.125 times the minimum inhibitory concentration (MIC)—the lowest amount of antimicrobial required to inhibit bacterial growth—and at normal (37°C) and febrile (41°C) temperatures, suggesting chlortetracycline would likely be effective whether given before or after the development of a febrile response.

WHEN TO USE

Feed at labeled doses ranging from 0.5 mg to 10 mg per pound of body weight per day for specific conditions and durations. Mix thoroughly into dry feed. Aureomycin requires a valid veterinary feed directive. Consult your veterinarian for proper use.

Phibro ANIMAL HEALTH CORPORATION®

AUREOMYCIN®

✓ FEWER INJECTIONS, HEALTHIER CALVES

At the USDA Meat Animal Research Center (USMARC), a 120-day feedlot study evaluated Aureomycin in high-risk calves. A total of 300 newly weaned calves were randomly assigned to two groups: one fed Aureomycin (10 mg/lb of bw/day) on days 5–9 post-arrival, and one control group with no in-feed antibiotics. BRD cases treated with injectable macrolides dropped 95% (1.3% vs. 25.3%) in Aureomycin-fed calves.[1]



-95.0%
REDUCTION IN CRITICALLY IMPORTANT THERAPEUTIC TREATMENTS

✓ LOWER MORBIDITY, HIGHER INTAKES



a–cTreatments with unlike superscripts differ ($P \leq 0.10$)

In a 2018 commercial feedlot study, 6,800 Holstein steers were assigned to four groups: Draxxin® only, Aureomycin only (three 5-day pulses), Draxxin + Terramycin®, and Draxxin + Aureomycin.

Draxxin + Aureomycin reduced BRD first pulls ≥ 40°C, % of enrolled in the first 30 days (7.0% vs. 8.9%) and total morbidity (20.0% vs. 24.9%) versus Draxxin alone. It also improved DMI (11.8 vs. 11.2 lb/day) and daily gain (+5.2%, 2.80 vs. 2.66 lb/day) compared to Draxxin alone.[2]

✓ A FLEXIBLE, PROVEN SOLUTION

Together these studies show Aureomycin reduces the reliance on critically important injectable antibiotics, which supports antibiotic stewardship and improves health and performance. With zero withdrawal time and compatibility in metaphylaxis programs, **Aureomycin offers producers a flexible, proven solution for managing BRD.**

Caution: Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug (Aureomycin) to use by or on the order of a licensed veterinarian.

Get early, in-feed control of bacterial diseases.
Reach out to your Phibro representative to learn more.
www.pahc.com | 800.677.4623

[1] Agga, et al., 2016. Appl. Environ. Mircrobiol. 82(24):7197-7204.
[2] Szasz, et al., 2018. Transl. Anim. Sci. 3(1):185–194.

HEALTHY ANIMALS. HEALTHY FOOD. HEALTHY WORLD.®

Phibro ANIMAL HEALTH CORPORATION®